Aktie A2P853 NUGENEREX IMMUNO-ONCOLOGY, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen NuGenerex Immuno-Oncology, Inc.

Aktien

A2P853

US67053X1028

NUGX

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
NUGENEREX IMMUNO-ONCOLOGY, INC. : Changes in Control or Registrant, Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021
NuGenerex Immuno-Oncology, Inc. has completed an IPO in the amount of $50.000004 million.
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)
NuGenerex Immuno-Oncology, Inc. Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment
NuGenerex to Seek Merger or Acquisition Opportunities
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine
NuGenerex Immuno-Oncology, Inc. has filed an IPO in the amount of $1 million.
Bintai Kinden Corporation Berhad Announces Memorandum of Understanding with Nugenerex Immuno-Oncology on New Business Opportunity (COVID-19 Vaccine)
Nugenerex Immuno-Oncology Closes $50 Million Financing Facility
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2P853 Aktie
  4. Nachrichten NuGenerex Immuno-Oncology, Inc.
  5. Andere Sprachen